462 related articles for article (PubMed ID: 30069581)
1. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
2. The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.
Manley BJ; Tennenbaum DM; Vertosick EA; Hsieh JJ; Sjoberg DD; Assel M; Benfante NE; Strope SA; Kim E; Casuscelli J; Becerra MF; Coleman JA; Hakimi AA; Russo P
Urol Oncol; 2017 Jan; 35(1):35.e1-35.e5. PubMed ID: 27567689
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
4. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Margulis V; Shariat SF; Rapoport Y; Rink M; Sjoberg DD; Tannir NM; Abel EJ; Culp SH; Tamboli P; Wood CG
Eur Urol; 2013 May; 63(5):947-52. PubMed ID: 23273681
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
6. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
8. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
[TBL] [Abstract][Full Text] [Related]
10. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
11. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA.
Manley BJ; Kim EH; Vetter JM; Potretzke AM; Strope SA
Int Braz J Urol; 2017; 43(3):432-439. PubMed ID: 28128914
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
13. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
14. Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era.
Tornberg SV; Visapää H; Kilpeläinen TP; Taari K; Järvinen R; Erkkilä K; Nisen H; Järvinen P
Scand J Urol; 2018; 52(5-6):419-426. PubMed ID: 30663485
[TBL] [Abstract][Full Text] [Related]
15. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study.
Cindolo L; Chiodini P; Brookman-May S; De Cobelli O; May M; Squillacciotti S; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Wirth MP; Dalpiaz O; Chromecki TF; Shariat SF; Sanchez-Chapado M; Santiago Martin Mdel C; Rocco B; Salzano L; Lotrecchiano G; Berardinelli F; Schips L
BJU Int; 2013 Sep; 112(5):578-84. PubMed ID: 23470199
[TBL] [Abstract][Full Text] [Related]
16. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.
McIntosh AG; Umbreit EC; Holland LC; Gu C; Tannir NM; Matin SF; Karam JA; Culp SH; Wood CG
Cancer; 2020 Sep; 126(17):3950-3960. PubMed ID: 32515845
[TBL] [Abstract][Full Text] [Related]
17. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
19. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
Kanao K; Mizuno R; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
J Urol; 2009 Feb; 181(2):480-5; discussion 485. PubMed ID: 19100568
[TBL] [Abstract][Full Text] [Related]
20. Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy.
Kalogirou C; Mulfinger P; Sokolakis I; Krebs M; Kübler H; Riedmiller H; Vergho D
Urol Int; 2017; 99(3):297-307. PubMed ID: 28624829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
